Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

257
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
257
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

568
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
568
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

305
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
305
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

451
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
451
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

802
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
802

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A systematic review of the determinants of vaccine hesitancy in the UK: Implications for future TB vaccine adoption.

BMC public health·2026
Same author

Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing.

Nature communications·2026
Same author

Inclusion of young adolescents in policy development for new tuberculosis vaccines.

The Lancet. Global health·2026
Same author

Diagnostic accuracy study of the multiplex Truenat MTB Ultima/COVID-19 assay for simultaneous detection of Tuberculosis and SARS-CoV2 (COVID-19).

PLOS global public health·2026
Same author

Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development.

The Lancet. Infectious diseases·2026
Same author

Genomic characterization of the emerging multidrug-resistant <i>Klebsiella pneumoniae</i> ST6668 clone in northern Italy, 2020-2025.

Microbiology spectrum·2026
Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026
Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026
Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026
Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026
Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026
Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026
See all related articles

Related Experiment Video

Updated: Nov 8, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.0K

Tests for tuberculosis infection: landscape analysis.

Yohhei Hamada1, Daniela Maria Cirillo2, Alberto Matteelli3

  • 1Institute for Global Health, University College London, London, UK y.hamada@ucl.ac.uk.

The European Respiratory Journal
|April 20, 2021
PubMed
Summary
This summary is machine-generated.

New tuberculosis infection tests show promise for improved accuracy and accessibility. Further evaluation is needed to support their global adoption and programmatic scale-up for better TB control.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.0K

Related Experiment Videos

Last Updated: Nov 8, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.0K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.0K

Area of Science:

  • Infectious Diseases
  • Diagnostics
  • Public Health

Background:

  • Current World Health Organization-endorsed tests for tuberculosis (TB) infection include the tuberculin skin test (TST) and two interferon-γ release assays (IGRAs).
  • IGRAs offer higher specificity than TST but require complex laboratory setups and are expensive.
  • Existing TB infection tests have limited ability to predict the development of active TB, highlighting the need for improved diagnostic tools.

Purpose of the Study:

  • To review the current landscape of diagnostic tests for tuberculosis infection.
  • To identify emerging tests with potential for improved performance and operational characteristics.

Main Methods:

  • A global web-based survey targeting diagnostic manufacturers was conducted.
  • The survey aimed to identify and characterize available and developing tests for TB infection.

Main Results:

  • Twenty tests for TB infection were identified, comprising 15 in vitro assays and five skin tests.
  • Many in vitro tests are whole-blood IGRAs utilizing ESAT-6 and CFP-10 antigens, with some employing novel assay formats like fluorescent lateral flow assays for easier decentralization.
  • Several skin tests also utilize ESAT-6 and CFP-10, alongside one utilizing a novel antigen specific to the Mycobacterium tuberculosis complex.

Conclusions:

  • Emerging TB infection tests possess the potential to enhance diagnostic accuracy, operational efficiency, and accessibility for end-users.
  • Limited published data across diverse populations and settings exists for most novel tests.
  • Standardized evaluation of these new tests is crucial for facilitating their endorsement and widespread programmatic implementation.